GlassScriptPhysician profile
Rizwanuddin M Farooqi
NPI 1548470974
$5,372.17
in general payments reported to CMS, 2019-2025
40 companies · $857 in 2025
The $857 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $151 · 2021: $895 · 2022: $1,196 · 2023: $1,055 · 2024: $690 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,454.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $655.27 | 2019-2025 | |
| Pfizer INC. | $526.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $440.10 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $298.97 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $293.52 | 2019-2022 | |
| Dexcom, INC. | $267.65 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $251.17 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $223.69 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $126.49 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.91 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $64.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.78 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $49.51 | 2023-2024 | Contrave |
| Gilead Sciences, INC. | $47.17 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwanuddin Farooqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.